CAII-IN-15 是一种强效的碳酸酐酶 II (CA II) 抑制剂,对 hCA II 的 IC50 为 10 nM,可提高 cGMP 水平、释放一氧化氮、减轻氧化应激,并在体外展现出神经保护活性,同时可抑制 NLRP3 炎症小体活化、减少神经元凋亡 (apoptosis)、降低兔的眼内压 (IOP),因此可用于青光眼的相关研究。
CAII-IN-15
产品编号: MS-R40253 分子式: C14H13N3O6S 分子量: 351.33
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

CAII-IN-15 是一种强效的碳酸酐酶 II (CA II) 抑制剂,对 hCA II 的 IC50 为 10 nM,可提高 cGMP 水平、释放一氧化氮、减轻氧化应激,并在体外展现出神经保护活性,同时可抑制 NLRP3 炎症小体活化、减少神经元凋亡 (apoptosis)、降低兔的眼内压 (IOP),因此可用于青光眼的相关研究。

生物实验数据

生物活性 CAII-IN-15 is a potent carbonic anhydrase II (CA II) inhibitor with an IC50 of 10 nM against hCA II that elevates cGMP levels, releases nitric oxide, alleviates oxidative stress, exhibits neuroprotective activity in vitro, inhibits NLRP3 inflammasome activation, reduces neuronal apoptosis, lowers intraocular pressure (IOP) in rabbits, and can therefore be used for research related to glaucoma.
IC50 & Target

hCA II

10 nM (IC50)

hCA IX

32 nM (IC50)

hCA I

430 nM (IC50)

hCA XII

19 nM (IC50)

NLRP3 inflammasome

 

体外研究
(In Vitro)

CAII-IN-15 (compound B6) (0.5 nM-5 mM; 15 min) 可强效且选择性地抑制重组人 CA II,其 IC50 为 10 nM;同时对 hCA I (IC50 = 430 nM)、hCA IX (IC50 = 32 nM) 和 hCA XII (IC50 = 19 nM) 表现出中等抑制活性。
CAII-IN-15 通过 Zn2+ 配位、与 THR199 和 GLN92 形成氢键以及与 PHE131 发生 π-π 堆积作用结合于 CA II 的活性位点,这一作用支撑了其强效抑制活性。
CAII-IN-15 (10 μM; 24 h) 可升高人小梁网 (HTM) 细胞内的 cGMP 水平,证实其可激活 NO/sGC/cGMP 信号通路。
CAII-IN-15 (5-20 μM; 4 h) 对氧糖剥夺 (OGD) 诱导的 SH-SY5Y 细胞损伤具有浓度依赖性神经保护作用。
CAII-IN-15 (10 μM; 24 h) 可抑制 LPS (MS-X54539) 诱导的 Müller 细胞中 IL-1β 和 NLRP3 炎症小体的表达升高。
CAII-IN-15 (10 μM; 4 h) 可抑制视网膜前体细胞 R28 中由 OGD/R 诱导的 ROS 水平升高。
CAII-IN-15 (0.032-100 μM; 24 h) 在多种眼细胞类型中表现出剂量依赖性细胞毒性。
CAII-IN-15 (1.56-50.00 μg/mL; 1 h) 在 1.56 μg/mL 至 50.00 μg/mL 的浓度下对兔红细胞无显著溶血活性,溶血率持续低于 5%,显示出优良的血液相容性。
CAII-IN-15 (0-30 μM) 在最高 30 μM 的浓度下对 hERG 钾通道无显著抑制作用,提示心律失常风险较低且心脏安全性良好。

ELISA Assay

Cell Line: human trabecular meshwork (HTM) cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Significantly Increased intracellular cGMP levels to approximately 15.8 nmol/L.

Cell Viability Assay

Cell Line: SH-SY5Y cells
Concentration: 5; 10; 20 μM
Incubation Time: 4 h
Result: Restored OGD-reduced cell viability to 88.10% (5 μM), 91.12% (10 μM), and 93.71% (20 μM).
Showed concentration-dependent neuroprotection.

ELISA Assay

Cell Line: lipopolysaccharide (LPS)-stimulated Müller cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Substantially reduced LPS-induced ASC speck counts and IL-1β concentrations.

Cell Viability Assay

Cell Line: conjunctival cells, human corneal epithelial cells (HCEC), human trabecular meshwork cells (HTMC), lens B3 cells, retinal R28 cells, and 661W cells
Concentration: 0.032; 0.16; 0.8; 4 μM (conjunctival cells); 0.8; 4; 20; 100 μM (HCEC, HTMC, B3, R28, 661W cells)
Incubation Time: 24 h
Result: Decreased conjunctival cell viability from 97.76% to 76.76% across tested concentrations, with 15.09% higher viability than brinzolamide at 0.032 μM.
Decreased HCEC viability from 99.67% to 76.00%, with 5.33% higher viability than brinzolamide at 100 μM.
Decreased HTMC viability from 99.83% to 91.00%, with 3.73% higher viability than brinzolamide at 4 μM.
Decreased B3 cell viability from 99.67% to 90.33%, with 3.09% higher viability than brinzolamide at 4 μM.
Decreased R28 cell viability from 95.90% to 70.67%, with 7.10% higher viability than brinzolamide at 4 μM.
Decreased 661W cell viability from 91.71% to 75.97%, with 10.86% higher viability than brinzolamide at 4 μM.
体内研究
(In Vivo)

CAII-IN-15 (compound B6) (0.05 mL 1% Carbomer 混悬液;眼部 (结膜囊滴注);单次给药;或每日 2 次,连续给药 28 天) 在兔体内展现出急性和慢性降眼压 (IOP) 功效。
CAII-IN-15 (0.1 mL 1% Carbomer 混悬液;经结膜囊局部滴注;单剂量) 在兔眼中表现出极低的眼刺激性。
CAII-IN-15 (100 μL 1% 溶液;局部 (眼内滴注);单次给药) 可在兔房水中释放一氧化氮。

Animal Model: Male New Zealand white rabbits ( 2-3 months old, 2-2.5 kg) bilateral intravitreally injected with 0.05 mL 5% hypertonic saline
Dosage: 0.05 mL in 1% carbomer suspension
Administration: topical (conjunctival sac instillation); single dose
Result: Achieved a maximum IOP reduction of -6.5 mmHg at 30 minutes post-administration.
Exhibited sustained efficacy lasting until 240 minutes.
Animal Model: Male New Zealand white rabbits ( 2-3 months old, 2-2.5 kg) bilateral intravitreally injected with with 0.1 mL Carbomer (MS-J88965)
Dosage: 0.05 mL in1% carbomer suspension
Administration: topical (conjunctival sac instillation); twice daily; 28 days
Result: Provided consistent additional IOP reduction throughout the core observation period (days 10-26), with peak differences of 3.0 mmHg recorded on days 14 and 17.
Animal Model: Male New Zealand white rabbits ( 2-3 months old, 2-2.5 kg)
Dosage: 0.1 mL in 1% carbomer suspension
Administration: topical (conjunctival sac instillation); single dose
Result: At 1 hour post-instillation, showed mild conjunctival hyperemia and minimal secretion with a total irritation score of 0.75.
Scores returned to baseline (0) by 2 hours.
Classified as a non-irritant (maximum score ≤1).
Animal Model: Male New Zealand white rabbits ( 2-3 months old, 2-2.5 kg)
Dosage: 1% solution, 100 μL
Administration: topical (ocular instillation); single dose
Result: Released nitric oxide at a concentration of 5.75-6.21 μM at 0.5 hour post-administration.
Decreased Nitric oxide release sharply at 1 hour and 1.5 hours post-administration.

化学信息

分子量 351.33
分子式 C14H13N3O6S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础